Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line.
Animals
Cell Line, Tumor
HEK293 Cells
Humans
Male
Mice
Phosphodiesterase 5 Inhibitors
/ pharmacology
Phosphoric Diester Hydrolases
/ metabolism
Piperazines
/ pharmacology
Protein Isoforms
/ metabolism
Purines
/ pharmacology
Second Messenger Systems
Sildenafil Citrate
/ pharmacology
Steroids
/ pharmacology
Sulfones
Tadalafil
/ pharmacology
Triazines
/ pharmacology
Vardenafil Dihydrochloride
/ pharmacology
LH
PDE5i
Sildenafil
Tadalafil
Vardenafil
hCG
Journal
Molecular and cellular endocrinology
ISSN: 1872-8057
Titre abrégé: Mol Cell Endocrinol
Pays: Ireland
ID NLM: 7500844
Informations de publication
Date de publication:
15 02 2022
15 02 2022
Historique:
received:
06
08
2021
revised:
26
10
2021
accepted:
01
12
2021
pubmed:
8
12
2021
medline:
5
4
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
Type 5 phosphodiesterase (PDE5) blockade by inhibitors (PDE5i) results in intracellular cyclic guanosine monophosphate (cGMP) increase and smooth muscle relaxation and are used for the treatment of men erectile dysfunction. Although they have high specificity for PDE5, these inhibitors are suspected to cross-interact also with cyclic adenosine monophosphate (cAMP)-specific PDEs, inducing the intracellular accumulation of this cyclic nucleotide and related testosterone increase, positively impacting male reproductive parameters. However, the link between the use of PDE5i and the activation of cAMP-mediated steroidogenesis is still unclear. We have investigated whether three PDE5i, sildenafil, tadalafil and vardenafil, cross-interacts with the high affinity cAMP-specific enzymes type 8A and 8B PDEs (PDE8A and PDE8B), in live, transfected mouse Leydig tumor (mLTC1) and human embryonic kidney (HEK293) cell lines in vitro. The PDE5i-induced production of cAMP-dependent testosterone and its precursor progesterone was evaluated as well. We have developed PDE8A/B biosensors and modified cyclic nucleotides confirming enzyme binding to cAMP, but not to cGMP, in our cell models. cAMP binding to PDE8A/B was displaced upon cell treatment with PDE5i, revealing that sildenafil, tadalafil and vardenafil have similar effectiveness in live cells, in vitro. The cross-interaction between PDE5i and PDE8A/B supports the gonadotropin-enhanced intracellular cAMP increase, occurring together with cGMP increase, as well as steroid synthesis. Indeed, we found that Leydig cell treatment by PDE5i increases progesterone and testosterone production triggered by gonadotropins. We demonstrated that PDE5i may interact with the cAMP-specific PDE8A and PDE8B, possibly inducing intracellular cAMP and sex steroid hormone increase. These findings support clinical data suggesting that PDE5i might increase testosterone levels in men.
Identifiants
pubmed: 34875337
pii: S0303-7207(21)00371-3
doi: 10.1016/j.mce.2021.111527
pii:
doi:
Substances chimiques
Phosphodiesterase 5 Inhibitors
0
Piperazines
0
Protein Isoforms
0
Purines
0
Steroids
0
Sulfones
0
Triazines
0
Vardenafil Dihydrochloride
5O8R96XMH7
Tadalafil
742SXX0ICT
Sildenafil Citrate
BW9B0ZE037
Phosphoric Diester Hydrolases
EC 3.1.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111527Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.